Anti-infection treatment for lung cancer patients
Lung cancer is one of the malignant neoplasms with high global morbidity and mortality rates, and, as a result of the effects of the tumor itself and its treatment, patients with lung cancer are highly susceptible to co-infection and anti-infection treatment is a key part of their comprehensive treatment.
I. Causes of vulnerability to lung cancer
1. Local factors: pulmonary cancer edema obstructs gas channels, resulting in a lack of fluid flow, creating hotbeds for bacterial breeding. At the same time, tumours can disrupt the normal barrier function of bronchial mucous membranes, weaken local defence mechanisms and make pathogens more accessible.
2. All-body factor: lung cancer is often accompanied by malnutrition and a significant decrease in body immunity. Anti-tumour treatments such as chemotherapy also inhibit bone marrow blood function while killing cancer cells, leading to a reduction in white cells, especially in the case of meso-particle cells, and a significant reduction in the resistance to infection. In addition, surgical trauma not only destroys the body ‘ s physical defence, but is also prone to lung infections such as falling pneumonia after long periods of bed rest.
II. Types of common infections and pathogens
1. Lung infections: most common, pathogen diversity. Bacteria such as pneumocococcal, copper-green pseudosyncs, yellow grapes and positive bacteria can cause disease; fungi such as white tremolic and fungus are frequently found in low-immuno-prevalence patients; and viruses such as influenza virus, mega-cell viruses are susceptible to infection during certain seasons or when the patient ‘ s immunity is extremely weak.
2. Respiratory infections: In addition to the lungs, upper respiratory infections are also rare, mostly caused by common viruses such as nasal viruses and coronal viruses, in the form of flue aldicarb and sores, which, if poorly controlled, can spread down to the lung.
3. Infection of the urinary system: lung cancer patients are susceptible to urinological infections due to long-term bed resting, the retention of catheters, etc., and coli and deformation are common pathogens, often associated with urinary tract irritation, e.g. urination, excrement and pain.
III. Principles for anti-infection treatment
1. Precision diagnosis: In case of suspected infection, the competent specimens, such as sluice, blood, urine, etc., shall be collected promptly for smearing, training and drug-sensitive testing. This is the cornerstone of the follow-up precision drug, which, although it takes time to develop, needs to be adapted to the empirical treatment after it is initiated.
2. Reasonable choice of drug: a combination of the infected area, possible pathogens and local epidemiological information, and the liver and kidney function of the patient. For example, in the case of serious lung infections, an experiential treatment with a combination of β-neamamine or aminomal sugar with anti-fashion symbiosis activity may be used before the pathogen is identified; sensitive drugs are selected after the return of the sensitisation results.
3. Individualized medication: dose adjustment and treatment process taking into account age, underlying disease, liver and kidney function. The reduction in liver and kidney function of elderly patients and the reduction in the metabolic excretion of drugs require appropriate reductions; patients with incomplete kidney function avoid the use of renal excretion and renal toxicity drugs, or dosages adjusted to the acetic anhydride removal rate.
IV. Therapeutic approach
1. Antibacterial treatment: appropriate antibacterial spectropharmaceuticals based on pathogens. In the case of pneumocococcal pneumonia, the preferred choice is penicillin G, and methyloxysilin-yellow grapepluccus (MRSA) infection, the choice is to use vancomicin, rhinazine, etc. The efficacy and adverse effects are closely monitored during the course of the drug use, and the general use of the drug is 48 – 72 hours to assess changes in body temperature, symptoms, laboratory indicators and, if this is not effective, to replace it in a timely manner.
2. Anti-Factivism treatment: After the diagnosis of fungi infection, fluconoxin is often the preferred type of infection for white pyrococcus; the fungi infection requires the use of trichococtocin, such as voliacin and Icraconcin, or pyrocin B and its lipids, which is usually long and takes weeks to months to monitor indicators of liver and kidney function, vision, etc., for which there are some toxic side effects.
3. Anti-virus treatment: In the case of influenza viruses, neurosamate inhibitors, such as Ostave, are best applied within 24 – 48 hours to shorten the path and reduce symptoms; megacellular viruses are commonly infected with drugs such as the former Lovey, with the same attention paid to adverse effects such as bone marrow inhibition, and blood routines are periodically reviewed.
Integrated support treatment
Anti-infection, while not neglecting integrated support. Improved nutritional support to supplement proteins, heat, etc. through intestine or intestine pathways to correct undernourishment of patients and improve immunity; assisted mist inhalation, diluted aqueous fluids for those who are not susceptible to coughing; and management of the hospital environment, periodic disinfection, ventilation and reduction of risk of cross-infection.
Anti-infection treatment for patients with lung cancer is a complex and fine task, requiring multidisciplinary collaboration, close monitoring of changes in conditions, dynamical adjustment programmes, effective control of infection, creation of conditions conducive to follow-up treatment for lung cancer and improvement of patient prognosis.
